Abstract: This disclosure provides immunogenic combinations that include a) an immunogenic component containing a peptide or polypeptide antigen of a respiratory pathogen; and b) an immunogenic component containing a nucleic acid encoding an antigen of the same respiratory pathogen, wherein the immunogenic components are formulated for concurrent, e.g., co-localized, administration. More specifically, the respiratory pathogen is respiratory syncytial virus (RSV). This disclosure also concerns provides the use of such immunogenic combinations, and methods for administering such immunogenic combinations to elicit an immune response specific for the respiratory pathogen.

Abstract: Immunogenic combinations that include a) an immunogenic component containing a peptide or polypeptide antigen of a respiratory pathogen; and b) an immunogenic component containing a nucleic acid encoding an antigen of the same respiratory pathogen, wherein the immunogenic components are formulated for concurrent administration are provided, as well as methods for making and for administering such immunogenic combinations to elicit an immune response specific for the respiratory pathogen.

Abstract: Immunogenic combinations that include a) an immunogenic component containing a peptide or polypeptide antigen of a respiratory pathogen; and b) an immunogenic component containing a nucleic acid encoding an antigen of the same respiratory pathogen, wherein the immunogenic components are formulated for concurrent administration are provided, as well as methods for making and for administering such immunogenic combinations to elicit an immune response specific for the respiratory pathogen.

Abstract: Combination immunogenic compositions capable of eliciting protection against both RSV and B. pertussis infection and disease are provided, including compositions which comprise a recombinant F protein analog of RSV, together with B. pertussis acellular (Pa) or whole cell (Pw) antigens.

Abstract: This disclosure provides methods for protecting infants against disease caused by respiratory syncytial virus (RSV) and Bordetella pertussis through maternal immunization using recombinant respiratory syncytial virus (RSV) and B. pertussis antigens to reduce the incidence or severity of RSV and pertussis infection in young infants.

Abstract: This disclosure provides methods for protecting infants against disease caused by respiratory syncytial virus (RSV) through maternal immunization using recombinant respiratory syncytial virus (RSV) antigens to reduce the incidence or severity of RSV infection in young infants.